2022-502023-21-00招募中3 期
A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 13 cycles.
Chemo Research S.L.53 个研究点 分布在 8 个国家目标入组 1,037 人开始时间: 2023年7月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,037
- 试验地点
- 53
- 主要终点
- Overall Pearl Index (PI) in non-breastfeeding women aged 18 to 35 years (at the time of trial enrolment).
研究概览
简要总结
To demonstrate the contraceptive efficacy of LVDS.
研究设计
- 分配方式
- Non-randomized
- 主要目的
- Clinical trial
- 盲法
- None
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •[Visit 1a:] Sexually active, postmenarcheal and premenopausal female subjects at risk of pregnancy including breastfeeding women.
- •[Visit 1a:] Be willing to state that, to her best knowledge, her male sexual partner/partners has/have not had a vasectomy or been previously diagnosed as infertile (not applicable to adolescents).
- •[Visit 1a:] Agree not to participate in any other clinical trials during the course of this trial (participation in a non-interventional study is allowed).
- •[Visit 1a:] Only for female subjects between the ages of 15 and 17 (inclusive) provided that: a. Applicable national, state and local laws allow subjects in this age group to consent/assent to receive contraceptive services, b. All applicable laws and regulations regarding the informed consent/assent of the subjects to participate in clinical trials are observed. c. All special radiation protection approval requirements have been confirmed by corresponding official approvals and the sponsor has authorised the recruitment of underage participants in writing to the trial site. (Adolescents will not be included in Czech Republic and Germany)
- •[Visit 1a:] Women who either a. have never used hormonal contraceptives before consent/assent (naïve users), or b. have used hormonal contraceptives in the past, but have had a hormonal contraceptive-free period before consent/assent and a full menstrual cycle during the drug-free period (previous users) or c. directly switch from another hormonal contraceptive (switchers).
- •[Visit 1a:] Only for subjects who were not pregnant and did not use hormonal contraception during the last 6 months before consent/assent: Regular cycles (i.e. cycle length between 24 and 35 days) during the last 6 months.
- •[Visit 1a:] Only for women who were pregnant within the last 6 months before consent/assent: At least 3 complete menstrual cycles after pregnancy. Breastfeeding women can be included 4 weeks after delivery irrespective of menstrual cycles post-delivery.
- •[Visit 1a:] Systolic blood pressure ≤ 140 mm Hg and diastolic blood pressure ≤ 90 mm Hg, subjects with controlled hypertension are allowed.
- •[Visit 1a:] A written informed consent/assent is available, prior to undergoing any trial-related procedure.
- •[Visit 1a:] Willing to use trial contraception for thirteen 28-day cycles.
- •[Visit 1a:] Be willing to have intercourse in each cycle of the trial without the need to use back-up contraceptive (not applicable to adolescents).
排除标准
- •[Visit 1a / Visit 1b:] Pregnancy or wish of pregnancy.
- •[Visit 1a:] Severe COVID-19 disease or less than 3 months after hospitalization due to a COVID-19 disease.
- •[Visit 1a:] Known HIV infection.
- •[Visit 1a:] Known current or chronic hepatitis B or C.
- •[Visit 1a / Visit 1b:] Prohibited previous medication/therapy (as given in the protocol).
- •[Visit 1a / Visit 1b:] Dependence on prohibited co-medication/- therapy (as given in the protocol).
- •[Visit 1a / Visit 1b:] Progestin-releasing intra-uterine device (IUD) or contraceptive implant received or in place within the last 2 months.
- •[Visit 1a:] Planned regular concomitant use of barrier contraceptive methods, spermicides, IUDs or other contraceptive measures.
- •[Visit 1a:] Subject is a member of the investigator’s or sponsor’s staff or a relative or family member thereof.
- •[Visit 1a:] Is in custody or submitted to an institution by a court order.
- •[Visit 1a / Visit 1b:] Any condition or any disease that, in the opinion of the investigator, may jeopardize protocol compliance or the scientific integrity of the trial.
- •[Visit 1a:] Subject is known to or suspected of not being able to comply with the trial protocol, the use of the trial medication or the use of the trial diary.
- •[Visit 1a: Additional exclusion criteria for the BMD subgroup (adolescents) (except for Czech Republic and Germany):] History of low trauma fracture(s) defined as a fracture that results from a fall from a standing height or less, excluding fingers, toes, face and skull.
- •[Visit 1a: Additional exclusion criteria for the BMD subgroup (adolescents) (except for Czech Republic and Germany):] Known medical conditions associated with low bone mass: a. Metabolic bone disease such as osteogenesis imperfecta, Paget’s disease of the bone, osteomalacia/rickets b. Rheumatoid arthritis c. Collagen vascular diseases such as Marfan’s syndrome and Erhlos-Danlos syndrome d. Chronic kidney disease e. Hyperparathyroidism and abnormal bone mineral metabolism (hypocalcemia/ hypercalcemia, hypophosphatemia/ hyperphosphatemia, hypomagnesemia).
- •[Visit 1a: Additional exclusion criteria for the BMD subgroup (adolescents) (except for Czech Republic and Germany):] Current or ever use of medications or supplements known to increase BMD including bisphosphonates, denosumab, teriparatide, abaloparatide, romosozumab, calcitonin, fluoride and strontium.
- •[Visit 1a: Additional exclusion criteria for the BMD subgroup (adolescents) (except for Czech Republic and Germany):] Treatment with medications that are known to decrease bone mass: a. Glucocorticoids (oral, intravenous, chronic inhaled, chronic extensive topical) within the previous 3 months. Oral/intravenous glucocorticoids (prednisone ≥ 2.5 mg daily for ≥ 3 months, or the equivalent) within the last 12 months. b. Depo-medroxyprogesterone acetate within the previous 24 months. Depo-medroxyprogesterone acetate for a duration of use greater than 2 years ever in life. c. Aromatase inhibitors and/or raloxifene within the previous 24 months. d. Heparin, warfarin, thiazolidinedione, SGLT-2 inhibitors, tricyclic antidepressants, chronic proton pump inhibitor (PPI) use, selective serotonin reuptake inhibitors (SSRIs) within the previous 3 months.
- •[Visit 1a: Additional exclusion criteria for the BMD subgroup (adolescents) (except for Czech Republic and Germany):] Conditions that preclude BMD measurement i.e. lumbar spine/bilateral hip surgery with hardware in place, abdominal clips, umbilical ring (not willing to remove) or weight that exceeds the DXA machine limitation.
- •[Visit 1b: Additional exclusion criterion for the BMD subgroup (adolescents) (except for Czech Republic and Germany):] BMD Z-score below -1.
- •[Visit 1a:] History of infertility.
- •[Visit 1a:] Known bleeding disorder or history of unexplained bleeding or bruising within the last 12 months prior to V1a.
- •[Visit 1a:] Unexplained amenorrhoea.
- •[Visit 1a:] Abnormal finding on pelvic, breast or ultrasound examination that in the investigator’s opinion contraindicates participation in the trial.
- •[Visit 1a:] Women with a Papanicolaou (Pap) smear reading low-grade squamous intraepithelial lesion (LGSIL) or higher at screening. Subjects with atypical squamous cells of undetermined significance (ASC-US) can be included if they are negative for high-risk human papilloma virus (HPV) strains.
- •[Visit 1a:] Known contraindication including: a. Active venous thromboembolic disorder and/or a VTE history including a known positive family history in a sibling or parent. b. Arterial and cardiovascular disease, past or present (e.g. myocardial infarction, cerebrovascular accident, ischemic heart disease). c. Major surgery with prolonged immobilisation. d. Diabetes mellitus with vascular involvement. e. Presence or history of severe hepatic disease as long as liver function values have not returned to normal. f. Presence or history of liver tumours (benign or malignant). g. Known severe renal insufficiency or acute renal failure. h. Known adrenal insufficiency. i. Known or suspected sex steroid sensitive malignancies, including breast cancer. j. Hypersensitivity to the active substance or to any of the excipients.
- •[Visit 1a:] Uncontrolled concomitant chronic diseases (i.e., not on a stable treatment dose for at least 2 months at the time of assent/consent).
结局指标
主要结局
Overall Pearl Index (PI) in non-breastfeeding women aged 18 to 35 years (at the time of trial enrolment).
Overall Pearl Index (PI) in non-breastfeeding women aged 18 to 35 years (at the time of trial enrolment).
次要结局
- [Secondary safety and tolerability:] Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF).
- [Secondary safety and tolerability:] Clinical laboratory parameters (haematology, biochemistry including estradiol levels, TSH and urinalysis).
- [Secondary safety and tolerability:] IP acceptability.
- [Secondary efficacy:] Overall PI in women aged ≤ 35 years and in women > 35 years (at the time of trial enrolment).
- [Secondary efficacy:] PI after correction for back-up contraception and sexual activity (evaluable cycles).
- [Secondary efficacy:] PI after correction for back-up contraception and sexual activity (evaluable cycles) in women aged ≤ 35 years and in women > 35 years (at the time of trial enrolment).
- [Secondary efficacy:] PI for method failure.
- [Secondary efficacy:] PI for method failure in women aged ≤ 35 years and in women > 35 years (at the time of trial enrolment).
- [Secondary efficacy:] Pregnancy ratio by life table analysis.
- [Secondary efficacy:] Pregnancy ratio by life table analysis in women aged ≤ 35 years and in women > 35 years (at the time of trial enrolment).
- [Secondary safety and tolerability:] Adverse events (AEs).
- [Secondary safety and tolerability:] Vital Signs.
- [Secondary safety and tolerability:] Physical examination.
- [Secondary safety and tolerability:] Gynaecological examination, incl. transvaginal ultrasound examination and cervical cytology.
- [Secondary safety and tolerability:] Mastodynia/mastalgia/dysmenorrhoea.
- [Secondary safety and tolerability:] Proportion of subjects with bleeding / spotting in each cycle.
- [Secondary safety and tolerability:] Proportion of subjects with absence of bleeding.
- [Secondary safety and tolerability:] Proportion of subjects with prolonged bleeding.
- [Secondary safety and tolerability:] Number of days per cycle and reference period with bleeding and with spotting.
- [Secondary safety and tolerability:] Number of bleeding / spotting episodes per reference period.
- [Secondary safety and tolerability:] Duration of bleeding / spotting episodes by cycle and reference period.
- [Exploratory (bone mineral density assessment): For adolescents (except for Czech Republic and Germany) (15-17 years old at the time of enrolment):] Mean absolute changes in lumbar spine (L1-L4) Z-score from baseline to V6/EDV (and VBS) as measured by DXA.
- [Exploratory (bone mineral density assessment): For adolescents (except for Czech Republic and Germany) (15-17 years old at the time of enrolment):] Mean absolute changes in Z-scores (femoral neck, total hip and total body less head [TBLH]) from baseline to V6/EDV (and VBS).
- [Exploratory (bone mineral density assessment): For adolescents (except for Czech Republic and Germany) (15-17 years old at the time of enrolment):] Mean absolute and percentage changes in lumbar spine, femoral neck, total hip and total body less head [TBLH] BMD from baseline to V6/EDV (and VBS) as measured by DXA.
- [Exploratory (bone mineral density assessment): For adolescents (except for Czech Republic and Germany) (15-17 years old at the time of enrolment):] Mean absolute and percentage changes in TBLH bone mineral content (BMC) from baseline to V6/EDV (and VBS) as measured by DXA.
- [Exploratory (bone mineral density assessment): For adolescents (except for Czech Republic and Germany) (15-17 years old at the time of enrolment):] Proportion of subjects with percentage changes in lumbar spine, femoral neck, total hip and TBLH BMD by categories (≥ 0%; < 0% to -1.5%, < -1.5% to -3%, < -3% to -5%, < -5% to -8% and < -8%) from baseline to V6/EDV (and VBS).
- [Exploratory (bone mineral density assessment): For adolescents (except for Czech Republic and Germany) (15-17 years old at the time of enrolment):] Proportion of subjects with absolute changes in Z-scores (lumbar spine, femoral neck, total hip and TBLH) by categories (≥ 0.5, < 0.5 to 0.3, < 0.3 to 0, < 0 to 0.3, < -0.3 to -0.5 and < -0.5) from baseline to V6/EDV (and VBS).
研究者
Chief Scientific Officer
Scientific
Chemo Research S.L.
研究点 (53)
Loading locations...
相似试验
招募中
3 期
Lessening Organ Dysfunction with VITamin C in septic ARDS2024-516394-78-00Assistance Publique Hopitaux De Paris800
进行中（未招募）
1 期
A 12-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 after 4- and 12-weeks of treatment in patients with coronary artery disease (CAD)Coronary artery diseaseEUCTR2017-001582-25-FIAstraZeneca AB200
进行中（未招募）
1 期
A 12-week, randomized, single-blind, placebo-controlled, multi-centre, parallel group, phase IIa study to evaluate efficacy, safety and tolerability of oral AZD5718 after 4- and 12-weeks of treatment in patients with coronary artery disease (CAD)EUCTR2017-001582-25-DKAstraZeneca AB200
进行中（未招募）
不适用
A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary diseaseMedDRA version: 9.1Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2007-004033-42-EEGlaxoSmithKline Research and Development Ltd740
进行中（未招募）
1 期
Effects of prucalopride on opioid induced constipation in patients with chronic non-cancer paiopioid induced constipation in subjects with chronic non-cancer painMedDRA version: 14.1Level: PTClassification code 10010774Term: ConstipationSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2009-015652-20-GBShire-Movetis NV174